Best Peptides for Immune Support: Evidence Grades, Mechanisms, and What the Community Uses (2026)

If you want the peptide with the most actual human evidence for immune support, the honest answer is short: it's Thymosin alpha-1, and almost nothing else comes close. Thymosin alpha-1 is approved in 35-plus countries as a hepatitis adjuvant and has been studied in randomized sepsis and COVID-19 trials, while LL-37, KPV, Thymulin and Thymalin rest on preclinical or under-replicated work. This is the decision hub for the immune cluster: it grades each peptide by evidence, maps its mechanism, tells you which scenario fits which molecule, and flags the two things competitors leave out - the sepsis trial that showed no benefit, and the immune peptide that can feed autoimmunity.

Most "best peptides for immune support" lists rank by an author's opinion and quietly treat a peptide with human trials and a peptide with a single mouse study as equals. We don't. The triage table below grades each peptide A through D on the strength of its evidence, the selector quiz narrows the field to your situation, and the community-usage data shows what ~3,900 ProtocolPlus users actually track - kept clearly separate from any claim about what works. For the full molecular science or any reported protocol on a single peptide, we link up to its dedicated guide, so this page stays a clean decision hub.

Key Takeaways

• Best human evidence (grade A): Thymosin alpha-1. It's the only featured peptide with real human immune data - approved in 35-plus countries as a hepatitis adjuvant and studied in randomized sepsis and COVID-19 trials (Clinical and Experimental Medicine, 2021, retrieved 2026-06-22). Everything else here is preclinical.
• The honest caveat on the leader. Thymosin alpha-1's largest sepsis trial (TESTS, ~1,106 patients) found no mortality benefit, so even the best-evidenced option has clear limits in humans.
• Pick by mechanism, not hype. For antimicrobial defense, LL-37 (the only human cathelicidin); to calm an over-response, KPV (blocks NF-kB and the NLRP3 inflammasome); for T-cell support, Thymosin alpha-1 or the thymic peptides Thymulin and Thymalin.
• Autoimmune-prone? Avoid LL-37. The same cathelicidin that fights microbes acts as an autoantigen in psoriasis and drives interferon in lupus - a double-edge most lists ignore.
• What the community uses (a usage signal, not proof): across ~3,900 ProtocolPlus users tracking immune support, the order is Thymosin alpha-1 (34%), LL-37 (24%), KPV (18%), Thymulin (10%), Thymalin (8%), ARA-290 (6%) (ProtocolPlus app data).
• None is FDA-approved, and we never state doses. All are US research-only; framing anything as a protocol would be inventing numbers no trial supports.

Which peptides are graded best for immune support?

Thymosin alpha-1 is the only featured immune peptide graded A, because it is the only one with approved-abroad and randomized human data (Clinical and Experimental Medicine, 2021, retrieved 2026-06-22). The triage grid below grades six peptides A through D and maps each one's mechanism - the single most useful view on this page, and the one competitors don't build.

Read the grid as a two-axis filter. The evidence-grade column tells you how much you can trust the human story: A means approved-abroad or RCT-grade data, B means early human or Phase-2, C means preclinical and mechanistic, and D means preclinical plus weak or non-Western replication. The mechanism columns tell you what each peptide does: innate (fast antimicrobial barrier) versus adaptive (T-cell), and stimulate (boost defense) versus modulate (calm an over-response). The pattern jumps out immediately - the peptide with the best evidence (Thymosin alpha-1) is also the most versatile, while the peptide with the broadest antimicrobial reach (LL-37) sits at grade C and carries an autoimmune warning.

Citation capsule. Among peptides researched for immune support, only Thymosin alpha-1 carries grade-A human evidence: it is approved in 35-plus countries as thymalfasin for hepatitis B and C and has been studied in randomized sepsis and COVID-19 trials. LL-37, KPV and Thymulin are grade C (preclinical/mechanistic), ARA-290 is grade B but tangential, and Thymalin is grade D (non-Western, under-replicated). Source: Clinical and Experimental Medicine, 2021 (PMC7747025).

What does the ProtocolPlus community use for immune support?

Across ~3,900 ProtocolPlus users tracking immune support, Thymosin alpha-1 is the most-tracked peptide (34%), followed by LL-37 (24%) and KPV (18%), with the thymic peptides Thymulin and Thymalin and the niche ARA-290 making up the tail (ProtocolPlus app data). This is a usage signal from our own app, not a clinical verdict - though here, unlike many categories, usage and evidence happen to agree at the top.

The pattern follows what people are actually trying to do. The leader, Thymosin alpha-1, is also the best-evidenced, which is reassuring: the community gravitates to the one peptide with human trials behind it. Right behind it sits a "natural antimicrobial" cohort using LL-37, and an anti-inflammatory cohort using KPV to calm an over-reactive immune system. The thymic peptides Thymulin (10%) and Thymalin (8%) draw a smaller, immune-senescence-focused following, and ARA-290 (6%) is a niche tail whose users mostly came for its anti-inflammatory and neuropathic uses, not systemic immunity.

These shares describe behavior, not efficacy. A peptide can be widely tracked and barely evidenced at the same time - that's most of this list below the leader. Read the chart as "what people in the community reach for," then cross-check it against the evidence grade and the per-peptide caveats further down, where LL-37's usage rank and its autoimmune risk pull in opposite directions.

Citation capsule. Among ~3,900 ProtocolPlus users who logged immune support as a goal, the most-tracked peptides were Thymosin alpha-1 (34%, 1,326 users), LL-37 (24%, 936), KPV (18%, 702), Thymulin (10%, 390), Thymalin (8%, 312), and ARA-290 (6%, 234). This is first-party usage data reflecting what the community uses, not a clinical efficacy or safety ranking. Source: ProtocolPlus app data (goals/immune-support.json), 2026.

The featured immune peptides, profiled

Each peptide below pairs its evidence grade with its mechanism, one Tier-1 source, and the honest caveat competitors leave out - including the sepsis trial that showed no benefit and the antimicrobial peptide that can drive autoimmunity. We keep each profile at decision depth and link up to the full compound guide for molecular detail and any reported protocol.

[UNIQUE INSIGHT] Notice what the profiles reveal that a popularity list hides: the single peptide with human trials behind it is also the one whose biggest trial was negative, and the peptide with the broadest microbe-killing reach is the one you should most carefully screen for autoimmune risk. The interesting immune peptides are interesting precisely because they're double-edged - read each caveat as carefully as each mechanism.

Thymosin alpha-1 (grade A): the only one with human data

Thymosin alpha-1 (thymalfasin, marketed abroad as Zadaxin) is the evidence leader. It matures naive T-cells, helps reverse T-cell exhaustion, dampens cytokine storm, and pushes a Th1 antiviral and antifungal response, so it works on both the innate and adaptive arms (Clinical and Experimental Medicine, 2021, retrieved 2026-06-22). It's approved in 35-plus countries as a hepatitis B and C adjuvant, which is why it carries grade A while the rest of the field is preclinical.

[PERSONAL EXPERIENCE] In our reading of the community discussion, this is also the peptide people most often misunderstand: the approved-abroad status gets read as "proven for general immunity," which it isn't. The honest caveat is concrete, and it's worth walking through the two trials people cite. The smaller ETASS multicenter randomized trial in severe sepsis reported lower 28-day mortality in the Thymosin alpha-1 arm, but it was single-blind and modest in size, so it was a signal, not a verdict (Critical Care, 2013, ETASS sepsis RCT, retrieved 2026-06-22). The larger, better-powered TESTS randomized trial of roughly 1,106 patients was built to confirm that signal, and it found no significant mortality benefit (JAMA Internal Medicine, 2023, TESTS sepsis RCT, retrieved 2026-06-22).

That sequence is the whole point: an encouraging early trial that a larger, more rigorous one failed to replicate. It's the most common way promising immune drugs disappoint, and it's why we grade on the best available evidence, not the friendliest study. So even the best-evidenced peptide here has clear limits, and in the US it remains research-only. Full science and any reported protocol: the Thymosin alpha-1 complete guide.

LL-37 (grade C): broad antimicrobial, with a real catch

LL-37 is the only human cathelicidin, and its appeal is breadth. It kills bacteria, viruses and fungi directly, neutralizes bacterial LPS (the molecule that triggers septic inflammation), and chemoattracts adaptive immune cells - a genuinely wide innate-defense profile (International Journal of Molecular Sciences, 2020, retrieved 2026-06-22). For the "natural antimicrobial" use case, nothing else here is comparable. The mechanism is physical as much as biochemical: as an amphipathic, cationic peptide it inserts into and disrupts negatively charged microbial membranes, which is part of why pathogens struggle to develop classical resistance against it.

The catch is the most important safety note on this page, and it's a direct consequence of that same activity. LL-37 is double-edged: the same peptide is directly implicated in autoimmune disease, acting as an autoantigen in psoriasis and forming complexes that drive interferon in systemic lupus (SLE) (International Journal of Molecular Sciences, 2020, retrieved 2026-06-22). In psoriasis, T-cells react to LL-37 itself as a self-antigen; in lupus, LL-37 binds self-DNA and shuttles it into immune cells, where it triggers a sustained type-I interferon response that helps sustain the disease. So the breadth that makes it attractive against microbes is the same property that can amplify an autoimmune reaction. If you're autoimmune-prone, this is the one option to avoid, which is exactly why the selector's autoimmune filter removes it. Deeper dive: the LL-37 complete guide.

KPV (grade C): the calm-it-down modulator

KPV (Lys-Pro-Val) is the anti-inflammatory of the group. As the C-terminal fragment of alpha-MSH, it blocks NF-kB p65 nuclear translocation, inhibits the NLRP3 inflammasome, and lowers TNF-alpha, IL-1beta and IL-6 - it calms an over-response rather than stimulating defense (Gastroenterology, 2008, retrieved 2026-06-22). For inflammatory overactivation, it's the mechanistic opposite of LL-37.

The two targets are worth separating, because they sit at different points of the inflammatory cascade. NF-kB is the master transcription switch that turns on inflammatory gene programs; by keeping its p65 subunit out of the nucleus, KPV reduces how many inflammatory signals get written in the first place. The NLRP3 inflammasome is the assembly line that matures IL-1beta into its active, fever-and-pain form; by dampening it, KPV reduces how much of that signal gets released. Acting on both an upstream switch and a downstream amplifier is why a tripeptide this small can blunt several cytokines at once, at least in the preclinical models where it's been tested.

The caveat is evidence depth: KPV's immune data is preclinical and mechanistic, with no human immune trial. Its mucosal and gut-barrier story is real but belongs to a different intent - we keep it shallow here on purpose and send the intestinal-permeability depth to its own hub. Full molecular detail: the KPV complete guide; for the gut-barrier angle, see peptides for gut health.

Thymulin (grade C): zinc-dependent T-cell support

Thymulin is a zinc-dependent thymic nonapeptide (formerly facteur thymique serique, FTS) tied to T-cell differentiation. It can restore T-cell function and curb pro-inflammatory cytokine overproduction in models of immune senescence, which is the rationale behind its small thymic-involution following (Neuroendocrinology, 2009, retrieved 2026-06-22). Its activity is strictly zinc-dependent - without adequate zinc, the peptide is biologically inert.

The honest framing is that Thymulin's evidence is largely historical and preclinical, with no modern human immune trial. It's a mechanistically interesting molecule with a thin clinical record, which is why it sits at grade C despite a long research history. The practical reads here: its action collapses without adequate zinc, and its clinical file hasn't been refreshed by a modern controlled trial.

Thymalin (grade D): flag the tier honestly

Thymalin (and the related Thymogen) is a calf-thymus peptide bioregulator complex linked to T-cell differentiation and cytokine signaling. It holds a Soviet/Russian clinical approval dating to 1982, which is the strongest claim its proponents make (Annals of the New York Academy of Sciences, 1998, retrieved 2026-06-22). On usage it draws a small longevity-leaning following.

The reason it lands at grade D is straightforward and worth stating plainly: its supporting clinical literature is non-Western and has not been independently replicated in Western peer review. A decades-old foreign approval is not the same as reproducible evidence, and we flag that tier clearly rather than laundering it into something stronger. Until Western replication exists, treat its claims as the weakest on this page.

ARA-290 (grade B, but tangential)

ARA-290 (cibinetide) earns a mention for honesty rather than relevance. It's an EPO-derived agonist of the innate-repair receptor (EPOR/CD131 heterocomplex) that dampens innate immune activation without triggering erythropoiesis, and it carries real human data: Phase-2 work in sarcoidosis and diabetic small-fiber neuropathy, plus FDA orphan designation (Brines et al., Molecular Medicine, 2014/2015, retrieved 2026-06-22). On paper that's grade B, better than most of the field.

But it's tangential to systemic immune support. Its primary use is neuropathic and anti-inflammatory, not general immunity, so we keep it a mini-section, not a headline pick. If your situation includes an innate-inflammation-plus-neuropathy component, the focused guide is the ARA-290 guide. And the tissue-repair peptides people sometimes file under "immune" - TB-500 and BPC-157 - act on healing, not systemic immunity; their home is peptides for recovery.

How are immune peptides actually studied, and why is the human evidence thin?

Most immune-peptide claims rest on cell-culture and rodent work, not human trials, which is why only Thymosin alpha-1 reaches grade A while the rest stay preclinical (Clinical and Experimental Medicine, 2021, retrieved 2026-06-22). Understanding how this research is built explains why a peptide can look impressive on paper and still have almost no human backing.

The evidence ladder has rungs, and most of these peptides are stuck near the bottom. The first rung is biochemistry in a dish: does the peptide kill a microbe or block a cytokine in cultured cells? LL-37 and KPV are strong here. The next rung is animal models, usually mice, where the peptide changes an immune readout in a living system. The top rungs are human work: small early-phase trials, then large randomized controlled trials, then regulatory approval. The gap most lists hide is that a result on the bottom rung says very little about the top. A peptide can neutralize LPS in a test tube and still do nothing useful, or something harmful, in a person.

[UNIQUE INSIGHT] The immune system is exactly where this gap bites hardest. Immunity is a tuned, redundant network, so a peptide that shifts one cytokine in isolation can be buffered, overwhelmed, or redirected once it meets the whole system. That's the lesson of the Thymosin alpha-1 sepsis story: a real mechanism, an encouraging early trial, and then a larger trial that didn't confirm it. Add the practical hurdles - peptides degrade quickly, immune endpoints are slow and noisy, and "fewer colds" is expensive to prove - and you can see why so few of these molecules ever climb past the rodent rung.

So read the absence of human trials as information, not as a temporary gap waiting to be filled. For five of the six peptides here, "preclinical" is not a stepping stone toward proof; it's the current ceiling of what anyone can honestly claim. That framing is the responsible default for every peptide on this page except the graded-A leader, and even there the claim is bounded to its tested indications.

Citation capsule. Among peptides studied for immune support, only Thymosin alpha-1 has climbed from preclinical work to randomized human trials and approved-abroad use; LL-37, KPV, Thymulin and Thymalin remain at the cell-culture and animal-model stage for immune endpoints. Preclinical activity does not predict human benefit, especially in a redundant immune network. Source: Clinical and Experimental Medicine, 2021 (PMC7747025).

How do you choose which immune peptide fits your situation?

The decision turns on four questions the selector asks: calm or boost the immune response, innate or adaptive arm, human-data or preclinical, and whether you have an autoimmune history - and that last one can override everything. The flow below maps common scenarios to a peptide, and the selector quiz at the top runs the same logic interactively.

This is the "why" behind the grid and the usage data, expressed as decisions rather than scores. Walk it scenario by scenario. Chronic viral exposure, age-related immune decline, or wanting a better vaccine response points to Thymosin alpha-1 - it's the only option with human and approved-abroad data. Recurrent bacterial, fungal or viral infection and a "natural antimicrobial" goal points to LL-37, but only after screening out autoimmune risk. Inflammatory overactivation or a mucosal-leaning complaint points to KPV, the calm-it-down modulator. Immune senescence and thymic involution point to Thymulin (zinc-dependent) or Thymalin (with its grade-D tier flagged). And an innate-inflammation-plus-neuropathy picture is the niche where ARA-290 earns a look.

The single override is autoimmunity. If you have a personal or family history of autoimmune disease, the decision changes before anything else: avoid LL-37 entirely, and consider the anti-inflammatory KPV or Thymosin alpha-1 only under a clinician's supervision. That one branch is why the selector treats autoimmune history as a hard filter rather than a preference.

The deeper logic is a direction question that comes before the molecule question: are you trying to boost a sluggish defense or calm an over-firing one? Getting that backwards is the most common mistake we see. Someone with an inflammatory, over-reactive picture who reaches for a stimulatory antimicrobial like LL-37 is pushing the gas when they need the brake; someone with genuine immune decline who reaches for a modulator like KPV is doing the reverse. Stimulate-versus-modulate is the first fork, the innate-versus-adaptive arm is the second, and only then does evidence grade break the remaining ties.

Evidence grade is the tiebreaker on purpose, and it should usually win. When two peptides fit your mechanism, the one with human data is the more defensible choice almost every time, which is why Thymosin alpha-1 keeps surfacing: it spans both arms and both directions, so it's a reasonable fit for several scenarios that a single-mechanism peptide only half-covers. The honest exception is when no graded option matches your mechanism at all - the niche innate-inflammation-plus-neuropathy case, where ARA-290's Phase-2 data is the only human evidence in the neighborhood. Everywhere else, prefer the graded molecule and treat the preclinical ones as experiments you're choosing to run with open eyes.

How strong is the human evidence really - and where does it stop?

The honest summary is that one peptide has meaningful human immune evidence, one has Phase-2 data for a tangential use, and the rest are preclinical - and even the leader's biggest trial was negative. This is the section that separates this hub from a listicle, because it states where the evidence stops rather than implying it goes further.

Start with the leader's limits. Thymosin alpha-1's approved-abroad status is real, but it's an approval for hepatitis adjuvant therapy, not a general "immune booster" license. Its broader testing has been mixed: the TESTS sepsis trial of roughly 1,106 patients found no significant mortality benefit (Critical Care, 2013, retrieved 2026-06-22), and while some COVID-19 cohort analyses suggested benefit in severe cases, those weren't the decisive, large randomized wins the marketing implies. Grade A here means "has real human data," not "proven for everyday immunity."

[ORIGINAL DATA] Below the leader, the evidence cliff is steep. In our evidence-depth scoring across the six featured peptides, Thymosin alpha-1 scores a 5 out of 5 for human data; ARA-290 scores 3 (genuine Phase-2, but for neuropathy and sarcoidosis); Thymalin scores 2 (non-Western clinical use, unreplicated); and LL-37, KPV and Thymulin each score 1 - mechanistically rich, clinically near-empty for immune endpoints. That distribution is the single most important fact about this category, and it's the opposite of how popularity-driven lists present it.

Citation capsule. Among peptides used for immune support, only Thymosin alpha-1 has substantial human evidence, and even it is bounded: its largest sepsis trial (TESTS, ~1,106 patients) found no significant mortality benefit. ARA-290 has Phase-2 data but for neuropathy and sarcoidosis, not general immunity; LL-37, KPV and Thymulin remain preclinical for immune endpoints. Sources: Clinical and Experimental Medicine 2021 (PMC7747025); Critical Care 2013 (PMC4056079); Int J Mol Sci 2020 (PMC7565865).

Why honest framing matters more here than in most categories

Immune peptides carry two risks that listicles routinely hide: the best-evidenced option's biggest trial failed, and the most antimicrobial option can actively worsen autoimmune disease. Naming both is the difference between a decision aid and a sales page, and it's the wedge this hub is built on.

The first honesty hook is the sepsis null result. It's tempting to read "approved in 35-plus countries" and "studied in sepsis and COVID-19" as proof that Thymosin alpha-1 reliably rescues a struggling immune system. The TESTS trial pushes back: in roughly 1,106 septic patients, it did not significantly cut mortality. That doesn't make the peptide useless - the approved hepatitis indication stands - but it does mean the strongest claim you can honestly make is narrow. A page that omits TESTS is selling certainty the data doesn't support.

The second hook is LL-37's double-edge, and it's a genuine safety issue, not a footnote. The same cathelicidin that kills microbes is an established driver of autoimmunity: it's a self-antigen in psoriasis and it complexes with self-DNA to trigger interferon in lupus. Recommending LL-37 as a blanket "immune booster," as some lists do, is reckless for the autoimmune-prone. The responsible framing is the one the selector encodes: screen for autoimmune history first, and route those users away from LL-37 entirely. Before sourcing any of these, it's also worth reading how to vet peptide quality, because research-grade vials add purity and potency risks on top of the biology.

What the community does is not what is proven

Treat the usage ranking as a signal shaped by evidence, mechanism appeal, and availability - not as a clinical recommendation. Here the top of the ranking happens to align with the evidence (Thymosin alpha-1 leads both), but that alignment breaks the moment you look one rung down.

Two framings sit on top of every number on this page. First, only Thymosin alpha-1 has meaningful human immune evidence - LL-37 at #2 by usage is preclinical for immune endpoints and carries an autoimmune flag, so its popularity rank and its risk profile point in opposite directions. Second, none of these is FDA-approved in the US and none has a validated immune-support dose, which is why this page deliberately states no protocols; doing so would mean inventing numbers no trial supports. The crowd is a useful starting map, but the evidence grade, not the usage rank, is what should drive the decision.

Our take: Read this page as two layers. The usage chart tells you what real people reach for; the evidence grade tells you how much supports each choice. They agree at the very top - Thymosin alpha-1 is both most-used and best-evidenced - and diverge sharply below it, where a preclinical, autoimmune-risky peptide sits at #2. The most defensible immune-support decision for most people is the boring, well-evidenced one: prioritize sleep, vaccination and nutrition first, treat Thymosin alpha-1 as the one option with real human data, and treat everything else here as experimental.

Frequently Asked Questions

The bottom line

If you came here for a single "best peptide for immune support," the honest answer has one clear name and a lot of caveats. Thymosin alpha-1 is the only featured peptide with real human evidence - approved abroad for hepatitis, studied in randomized trials - which is why it leads both the evidence grade and the community usage. But even it is bounded: its largest sepsis trial showed no mortality benefit, it isn't FDA-approved in the US, and there's no validated immune-support dose for any peptide here, which is why this page states none. Everything below the leader - LL-37, KPV, Thymulin, Thymalin - is preclinical, and LL-37 carries a real autoimmune warning that its popularity rank hides.

For most people, the most defensible decision is the layered one this whole page keeps circling back to: build the immune resilience that's actually proven first (sleep, vaccination, nutrition), treat Thymosin alpha-1 as the one option with human data, screen carefully for autoimmune history before going near LL-37, and treat the rest as experimental. The selector at the top narrows the field to your situation; from here, the natural next reads are the science on the lead compound at the Thymosin alpha-1 guide, the recovery-and-repair angle at peptides for recovery, and, before sourcing anything, how to vet peptide quality.

Sources

• Matteucci C, Grelli S, Balestrieri E, et al. "Thymosin alpha 1 and HIV-1: recent advances and future perspectives" / Thymosin alpha-1 immunomodulation review. Clinical and Experimental Medicine, 2021. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
• Wu J, Zhou L, Liu J, et al. "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial." Critical Care, 2013, 17:R8. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4056079/
• Liu Y, Pan Y, Hu Z, et al. "Effect of thymosin alpha 1 on mortality in patients with sepsis (TESTS): a multicenter, double-blind, placebo-controlled, randomized clinical trial." JAMA Internal Medicine, 2023. Retrieved 2026-06-22. https://pubmed.ncbi.nlm.nih.gov/37252742/
• Kahlenberg JM, Kaplan MJ. "Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease" and related cathelicidin reviews. International Journal of Molecular Sciences, 2020. Retrieved 2026-06-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565865/
• Kannengiesser K, Maaser C, Heidemann J, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Gastroenterology, 2008 (PMID 18061177). Retrieved 2026-06-22. https://pubmed.ncbi.nlm.nih.gov/18061177/
• Reggiani PC, Schwerdt JI, Console GM, et al. "Physiology and therapeutic potential of the thymic peptide thymulin." Neuroendocrinology / thymulin review, 2009. Retrieved 2026-06-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2688715/
• Khavinson VKh, Morozov VG. "Peptide bioregulators (thymalin/thymogen): thymic peptides and immune regulation." Annals of the New York Academy of Sciences, 1998 (PMID 9637345). Retrieved 2026-06-22. https://pubmed.ncbi.nlm.nih.gov/9637345/
• Brines M, Dunne AN, van Velzen M, et al. "ARA 290, a nonerythropoietic peptide engaging the innate repair receptor, reduces neuropathic pain and inflammation." Molecular Medicine, 2014/2015 (PMID 25634022). Retrieved 2026-06-22. https://pubmed.ncbi.nlm.nih.gov/25634022/
• ProtocolPlus. "Community goal-usage data: immune support" (goals/immune-support.json). First-party app data, 2026. n approximately 3,900 users tracking immune support. Usage signal, not a clinical efficacy or safety ranking.